MX2008011138A - Treatment of tendinopathy by inhibition of molecules that contribute to cartilage formation. - Google Patents
Treatment of tendinopathy by inhibition of molecules that contribute to cartilage formation.Info
- Publication number
- MX2008011138A MX2008011138A MX2008011138A MX2008011138A MX2008011138A MX 2008011138 A MX2008011138 A MX 2008011138A MX 2008011138 A MX2008011138 A MX 2008011138A MX 2008011138 A MX2008011138 A MX 2008011138A MX 2008011138 A MX2008011138 A MX 2008011138A
- Authority
- MX
- Mexico
- Prior art keywords
- tendon
- use according
- enzyme
- tendinopathy
- group
- Prior art date
Links
- 208000000491 Tendinopathy Diseases 0.000 title claims abstract description 25
- 238000011282 treatment Methods 0.000 title claims description 8
- 230000005764 inhibitory process Effects 0.000 title description 4
- 230000022159 cartilage development Effects 0.000 title description 2
- 210000002435 tendon Anatomy 0.000 claims abstract description 27
- 210000000845 cartilage Anatomy 0.000 claims abstract description 8
- 201000004415 tendinitis Diseases 0.000 claims abstract description 7
- 206010043255 Tendonitis Diseases 0.000 claims abstract description 6
- 230000015572 biosynthetic process Effects 0.000 claims abstract description 6
- 208000014674 injury Diseases 0.000 claims abstract description 4
- 208000004760 Tenosynovitis Diseases 0.000 claims abstract description 3
- 208000013525 paratenonitis Diseases 0.000 claims abstract description 3
- 230000008733 trauma Effects 0.000 claims abstract description 3
- 238000000034 method Methods 0.000 claims abstract 3
- 230000000694 effects Effects 0.000 claims description 10
- 239000003814 drug Substances 0.000 claims description 5
- 229940079593 drug Drugs 0.000 claims description 4
- 238000003786 synthesis reaction Methods 0.000 claims description 4
- 210000001519 tissue Anatomy 0.000 claims description 4
- 229920002683 Glycosaminoglycan Polymers 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 108010067219 Aggrecans Proteins 0.000 claims description 2
- 108090000790 Enzymes Proteins 0.000 claims 6
- 102000004190 Enzymes Human genes 0.000 claims 6
- 239000003795 chemical substances by application Substances 0.000 claims 6
- 150000001875 compounds Chemical class 0.000 claims 6
- 102000004169 proteins and genes Human genes 0.000 claims 3
- 108090000623 proteins and genes Proteins 0.000 claims 3
- 229920002971 Heparan sulfate Polymers 0.000 claims 2
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 claims 2
- 102000016611 Proteoglycans Human genes 0.000 claims 2
- 108010067787 Proteoglycans Proteins 0.000 claims 2
- 101150106167 SOX9 gene Proteins 0.000 claims 2
- 101710172711 Structural protein Proteins 0.000 claims 2
- 102000004896 Sulfotransferases Human genes 0.000 claims 2
- 108090001033 Sulfotransferases Proteins 0.000 claims 2
- 102000040945 Transcription factor Human genes 0.000 claims 2
- 108091023040 Transcription factor Proteins 0.000 claims 2
- 108090000992 Transferases Proteins 0.000 claims 2
- 102000004357 Transferases Human genes 0.000 claims 2
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 claims 2
- VSKBNXJTZZAEPH-NSEZLWDYSA-N (3r,4r,5s,6r)-3-amino-6-(hydroxymethyl)oxane-2,4,5-triol;sulfuric acid Chemical compound OS(O)(=O)=O.N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O VSKBNXJTZZAEPH-NSEZLWDYSA-N 0.000 claims 1
- MSWZFWKMSRAUBD-GASJEMHNSA-N 2-amino-2-deoxy-D-galactopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@H](O)[C@@H]1O MSWZFWKMSRAUBD-GASJEMHNSA-N 0.000 claims 1
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 claims 1
- 102100036601 Aggrecan core protein Human genes 0.000 claims 1
- 241000283690 Bos taurus Species 0.000 claims 1
- 241000282472 Canis lupus familiaris Species 0.000 claims 1
- 101710132601 Capsid protein Proteins 0.000 claims 1
- 241000700198 Cavia Species 0.000 claims 1
- 241000282693 Cercopithecidae Species 0.000 claims 1
- 229920001287 Chondroitin sulfate Polymers 0.000 claims 1
- 102100031192 Chondroitin sulfate N-acetylgalactosaminyltransferase 1 Human genes 0.000 claims 1
- 102100031263 Chondroitin sulfate N-acetylgalactosaminyltransferase 2 Human genes 0.000 claims 1
- 102100029318 Chondroitin sulfate synthase 1 Human genes 0.000 claims 1
- 101710111960 Chondroitin sulfate synthase 1 Proteins 0.000 claims 1
- 102000000503 Collagen Type II Human genes 0.000 claims 1
- 108010041390 Collagen Type II Proteins 0.000 claims 1
- AEMOLEFTQBMNLQ-AQKNRBDQSA-N D-glucopyranuronic acid Chemical compound OC1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-AQKNRBDQSA-N 0.000 claims 1
- 241000283086 Equidae Species 0.000 claims 1
- 241000282326 Felis catus Species 0.000 claims 1
- OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 claims 1
- OVRNDRQMDRJTHS-RTRLPJTCSA-N N-acetyl-D-glucosamine Chemical compound CC(=O)N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-RTRLPJTCSA-N 0.000 claims 1
- MBLBDJOUHNCFQT-LXGUWJNJSA-N N-acetylglucosamine Natural products CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO MBLBDJOUHNCFQT-LXGUWJNJSA-N 0.000 claims 1
- 241000283973 Oryctolagus cuniculus Species 0.000 claims 1
- 241001494479 Pecora Species 0.000 claims 1
- 108010066816 Polypeptide N-acetylgalactosaminyltransferase Proteins 0.000 claims 1
- 241000288906 Primates Species 0.000 claims 1
- 241000283984 Rodentia Species 0.000 claims 1
- 241000282887 Suidae Species 0.000 claims 1
- 102000003698 Syndecan-3 Human genes 0.000 claims 1
- 108090000068 Syndecan-3 Proteins 0.000 claims 1
- 208000021945 Tendon injury Diseases 0.000 claims 1
- 108010065282 UDP xylose-protein xylosyltransferase Proteins 0.000 claims 1
- DQQDLYVHOTZLOR-OCIMBMBZSA-N UDP-alpha-D-xylose Chemical group C([C@@H]1[C@H]([C@H]([C@@H](O1)N1C(NC(=O)C=C1)=O)O)O)OP(O)(=O)OP(O)(=O)O[C@H]1OC[C@@H](O)[C@H](O)[C@H]1O DQQDLYVHOTZLOR-OCIMBMBZSA-N 0.000 claims 1
- AEMOLEFTQBMNLQ-UHFFFAOYSA-N beta-D-galactopyranuronic acid Natural products OC1OC(C(O)=O)C(O)C(O)C1O AEMOLEFTQBMNLQ-UHFFFAOYSA-N 0.000 claims 1
- 229940059329 chondroitin sulfate Drugs 0.000 claims 1
- 108010008408 chondroitin sulfate N-acetylgalactosaminyltransferase-1 Proteins 0.000 claims 1
- 229960002442 glucosamine Drugs 0.000 claims 1
- 229920001184 polypeptide Polymers 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims 1
- -1 versican Proteins 0.000 claims 1
- 208000023835 Tendon disease Diseases 0.000 abstract description 5
- 210000000968 fibrocartilage Anatomy 0.000 abstract description 3
- 208000013515 tendinosis Diseases 0.000 abstract description 3
- 238000002560 therapeutic procedure Methods 0.000 abstract description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 3
- 230000003412 degenerative effect Effects 0.000 abstract 2
- 208000012514 Cumulative Trauma disease Diseases 0.000 abstract 1
- 230000006866 deterioration Effects 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 230000008929 regeneration Effects 0.000 abstract 1
- 238000011069 regeneration method Methods 0.000 abstract 1
- 102000005741 Metalloproteases Human genes 0.000 description 6
- 108010006035 Metalloproteases Proteins 0.000 description 6
- 102000008186 Collagen Human genes 0.000 description 5
- 108010035532 Collagen Proteins 0.000 description 5
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 5
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 5
- 229920001436 collagen Polymers 0.000 description 5
- 210000002744 extracellular matrix Anatomy 0.000 description 5
- 239000000835 fiber Substances 0.000 description 5
- TYIRBZOAKBEYEJ-UHFFFAOYSA-N 2-(1,3-dimethyl-2,6-dioxopurin-7-yl)ethyl 2-[1-methyl-5-(4-methylbenzoyl)pyrrol-2-yl]acetate Chemical compound C1=CC(C)=CC=C1C(=O)C(N1C)=CC=C1CC(=O)OCCN1C(C(=O)N(C)C(=O)N2C)=C2N=C1 TYIRBZOAKBEYEJ-UHFFFAOYSA-N 0.000 description 3
- 206010066371 Tendon pain Diseases 0.000 description 3
- 239000003246 corticosteroid Substances 0.000 description 3
- 229960001334 corticosteroids Drugs 0.000 description 3
- 102000012422 Collagen Type I Human genes 0.000 description 2
- 108010022452 Collagen Type I Proteins 0.000 description 2
- 101800001224 Disintegrin Proteins 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 102000002274 Matrix Metalloproteinases Human genes 0.000 description 2
- 108010000684 Matrix Metalloproteinases Proteins 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 210000002808 connective tissue Anatomy 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 102000016284 Aggrecans Human genes 0.000 description 1
- 102000004237 Decorin Human genes 0.000 description 1
- 108090000738 Decorin Proteins 0.000 description 1
- 229940124761 MMP inhibitor Drugs 0.000 description 1
- 206010029113 Neovascularisation Diseases 0.000 description 1
- 102000002938 Thrombospondin Human genes 0.000 description 1
- 108060008245 Thrombospondin Proteins 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 210000001361 achilles tendon Anatomy 0.000 description 1
- 108010003059 aggrecanase Proteins 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000002308 calcification Effects 0.000 description 1
- 210000001608 connective tissue cell Anatomy 0.000 description 1
- 238000000315 cryotherapy Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 230000004066 metabolic change Effects 0.000 description 1
- 230000004660 morphological change Effects 0.000 description 1
- 210000001074 muscle attachment cell Anatomy 0.000 description 1
- 210000000651 myofibroblast Anatomy 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 230000007331 pathological accumulation Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 238000000554 physical therapy Methods 0.000 description 1
- 230000008707 rearrangement Effects 0.000 description 1
- 238000007634 remodeling Methods 0.000 description 1
- 230000003637 steroidlike Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Biotechnology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
The invention provides methods for treating tendinopathy. The disorders treated or prevented include, for example tendinitis, tendonitis, tendinosis, paratendinitis, tenocynovitis, tendon overuse injury and trauma, peritendinitis, paratenonitis, or other tendon degenerative disorders. The disclosed therapeutic methods include administering to a patient an inhibitor of molecules involved in cartilage or fibrocartilage formation in tendinopathic tendon in an amount effective to treat or prevent a tendon degenerative disorder, slow tendon deterioration, restore tendon healthy structure, stimulate tendon regeneration, and/or maintain tendon mass and/or quality.
Description
TENDINOPATHY TREATMENT FOR INHIBITION OF MOLECULES THAT CONTRIBUTE TO CARTILAGE FORMATION
FIELD OF THE INVENTION The technical field of the invention refers to the treatment of tendinopathy by reducing the production of cartilage tissue and / or fibrocartilage in damaged tendons. The invention also relates to the inhibition of molecules involved in the production of cartilage and / or fibrocartilage in damaged tendons. BACKGROUND OF THE INVENTION Tendinopathy is a general term used to describe various types of tendon disorders. The term "tendinitis" - which means "tendon inflammation" - is often used to describe tendon problems, but inflammation is seldom the cause of tendon pain.Most commonly, tendon pain is presently a symptom of a series of micro-tears in the connective tissue in or around the tendon, more appropriately called tendinosis Other tendon disorders include tendon pain, due to collagen degeneration with fiber disorientation, increased mucoid ground substance in the tendon, calcification Excessive use of tendon, vascularization, aging, tendon friction against a body protrusion Tendinopathy is used by a number of expert tendon producers to describe these conditions, often characterized as tendonitis, tendinosis, paratendinitis, tenosynovitis , paratenonitis, injuries due to excessive tendon use, and trauma, collectively Khan et al., S ports Med 27: 393-408 (1999). Normal tendon tissue is composed of densely packed connective tissue, with regularly arranged beams of collagen fibers running in the same direction in primary, secondary and tertiary fiber bundles, which have high fracture resistance. Scattered between these fibers are tapering, flat tenocytes, which synthesize the viscous extracellular matrix (ECM) rich in type I collagen. Beams of type I collagen provide the tendon flexibility and structural support. In healthy tendons, there is a dynamic balance between the synthesis and degradation of the ECM. Tendinopathy, however, adversely affects this balance and results in rearrangement and structural disorganization of the collagen fibers. The disorganization of the collagen bundles provides the tendon with the appearance of cartilage. The fibroblasts, myofibroblasts, neovascularization and pathological accumulation of glycosaminoglycans (GAGs) in the ECM are clearly remarkable in tendinopathic tissue. Tallón et al., Med Sci Sports Exerc 33 (12): 1983-90 (2001); Khan et al., Sports Med 27 (6): 393-408 (1999). Metabolic and morphological changes in a damaged tendon result in pain and susceptibility to tearing and rupture. Currently, the degradation and remodeling of a damaged tendon NDE is believed to be caused by the release of metalloproteinases from resident connective tissue cells and invading inflammatory cells that are capable of degrading macromolecules of matrix, such as aggrecans, decorin and biblicans. These metalloproteinases include MMP
(Matrix metalloproteinases), ADAMs (One disintegrin and metalloproteinase), and ADAMTs (One disintegrin and metalloproteinase with thrombospondin portions, such as aggrecanase). Riley G., Expert Rev Mol Med 7 (5) -l-23 (2005); Rees et al., Biochem J 350: 180-188 (2000). However, clinical trials of broad spectrum MMP inhibitors were not successful in the treatment of osteoarthritis, which has pathological similarities with tendinopathy. Clark et al., Expert Opin Ther Targets 7 (l): 19-34 (2003). Therefore, inhibition of metalloproteinases is not likely to be effective in the treatment of tendinopathy. However, in highly stressed tendons, such as the supraspinatus and achilles tendons, a minimum level of metalloproteinase activity may be necessary to provide the tendon with an optimal level of ECM. Riley G., Expert Rev Mol Med 7 (5): l-23 (2005). Currently, there are several standard operative and non-operative tendinopathy treatments. Non-operative measures include rest, cryotherapy, activity modification, physiotherapy, nonsteroidal anti-inflammatory drugs (NSAIDs) and corticosteroids. The modification of activity and rest, helps to maintain patients with some of these conditions, but a significant clinical population remains who are not treatable with these therapies. Due to widespread use, oral anti-inflammatory medications have not proven useful in controlled studies, and may have undesirable side effects. Some studies also suggest that non-steroidal medication can currently have an adverse effect on the healing process because to relieve pain, the patient is allowed to ignore the early symptoms of tendinopathy. Corticosteroids are normally used to reduce inflammation in tissues, but the use of such drugs to treat tendinopathy is not recommended, particularly because corticosteroids inhibit collagen synthesis. Several studies have observed a
Claims (14)
- CLAIMS Having described the invention as above, property is claimed as contained in the following: 1. Use of a compound that reduces the formation of cartilage-specific proteoglycans, in the manufacture of a drug to treat tendinopathy.
- 2. Use according to claim 1, wherein the compound reduces the activity of an enzyme or other protein involved in the synthesis of cartilage.
- 3. Use according to claim 2, wherein the compound directly or indirectly inhibits the function of the enzyme or protein.
- 4. Use according to claim 2 or claim 3, wherein the compound inhibits the expression of the enzyme or protein.
- 5. Use according to any one of claims 2 to 4, wherein the enzyme is selected from the group consisting of UDP-D-xylose: core protein β-D-xylosyltransferases, transacerase Gal, transferase GlcA, transferase GlcNAc, sulfotransferases, chondroitin sulfate synthases and heparin sulfate sulfotransferases.
- 6. Use according to claim 5, wherein the enzyme is selected from the group consisting of chondroitin sulfate N-acetylgalactosaminyltransferase 1 (CS-GalNAcT-1), chondroitin sulfate N-acetylgalactosaminyltransferase 2 (CS-GalNAcT-2) , polypeptide galactosamine N-acetylgalactosaminyltransferase 1 (GA1NT-1), and eparin sulphate (glucosamine) 3-0-sulfotransferase 1 (Hs3stl).
- 7. Use according to claim 1, wherein the compound reduces the expression of a specific structural protein of the cartilage.
- 8. Use according to claim 1, wherein the compound reduces the activity of transcription factors involved in the expression of the specific structural protein of the cartilage.
- 9. Use according to claim 8, wherein the transcription factor is Sox9.
- 10. Use according to any of claims 1 to 9, wherein the proteoglycan is selected from the group consisting of aggrecan, versican, syndecan-3, and type II collagen.
- 11. Use according to any of claims 1 to 10, wherein the tendinopathy is selected from the group consisting of tendinitis, tendonitis, tendonosis, paratendinitis, tenosynovitis, tendon injury, tendon trauma, perin- tenndinitis and paratenonitis.
- 12. Use according to any of claims 1 to 11, wherein the medicament is administered to a patient, selected from the group consisting of primates, monkeys, rodents, sheep, rabbits, dogs, guinea pigs, pigs, horses, cows and cats
- 13. Method for identifying a useful agent in the treatment of tendinopathy, characterized in that it comprises administering a test agent to a subject in need of treatment, and measuring the ability of the agent to inhibit the activity of an enzyme involved in the synthesis of glycosaminoglycans in the tendon tissue.
- 14. Method according to claim 13, characterized in that it further comprises the steps of (a) providing at least one test component selected from the group consisting of CS-GalNAcT-1, CS-GalNAct2, heparin sulfate (glucosamine) 3 -0-sulfotransferase 1, GalNT-1 and Sox9; (b) combining the sample with a test agent; (c) measuring the activity of the sample component in response to the test agent; and (d) determining whether the test agent inhibits the activity of the sample component.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US77916506P | 2006-03-03 | 2006-03-03 | |
| PCT/US2007/063177 WO2007103787A2 (en) | 2006-03-03 | 2007-03-02 | Treatment of tendinopathy by inhibition of molecules that contribute to cartilage formation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2008011138A true MX2008011138A (en) | 2008-09-08 |
Family
ID=38190750
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2008011138A MX2008011138A (en) | 2006-03-03 | 2007-03-02 | Treatment of tendinopathy by inhibition of molecules that contribute to cartilage formation. |
Country Status (8)
| Country | Link |
|---|---|
| EP (1) | EP1991276A2 (en) |
| JP (1) | JP2009533321A (en) |
| CN (1) | CN101432026A (en) |
| AU (1) | AU2007223383A1 (en) |
| BR (1) | BRPI0708527A2 (en) |
| CA (1) | CA2644708A1 (en) |
| MX (1) | MX2008011138A (en) |
| WO (1) | WO2007103787A2 (en) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009061368A1 (en) * | 2007-11-06 | 2009-05-14 | Benaroya Research Institute | Inhibition of versican with sirna and other molecules |
| DK3169334T3 (en) * | 2014-07-16 | 2021-07-05 | Ethris Gmbh | RNA FOR USE FOR TREATMENT OF LINK OR TENSE INJURIES |
| CN110520532B (en) * | 2017-03-31 | 2024-02-13 | 学校法人爱知医科大学 | Antisense nucleic acids that hinder chondroitin sulfate biosynthesis |
| RU2757081C1 (en) * | 2020-09-21 | 2021-10-11 | Федеральное государственное бюджетное образовательное учреждение высшего образования "Московская государственная академия ветеринарной медицины и биотехнологии - МВА имени К.И. Скрябина" (ФГБОУ ВО МГАВМиБ - МВА имени К.И. Скрябина) | Method for stimulating reparative regeneration in tendopathies |
-
2007
- 2007-03-02 MX MX2008011138A patent/MX2008011138A/en unknown
- 2007-03-02 BR BRPI0708527-3A patent/BRPI0708527A2/en not_active Application Discontinuation
- 2007-03-02 WO PCT/US2007/063177 patent/WO2007103787A2/en not_active Ceased
- 2007-03-02 EP EP07757795A patent/EP1991276A2/en not_active Withdrawn
- 2007-03-02 CA CA002644708A patent/CA2644708A1/en not_active Abandoned
- 2007-03-02 CN CNA2007800156766A patent/CN101432026A/en active Pending
- 2007-03-02 JP JP2008558476A patent/JP2009533321A/en active Pending
- 2007-03-02 AU AU2007223383A patent/AU2007223383A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| JP2009533321A (en) | 2009-09-17 |
| EP1991276A2 (en) | 2008-11-19 |
| AU2007223383A1 (en) | 2007-09-13 |
| CN101432026A (en) | 2009-05-13 |
| WO2007103787A2 (en) | 2007-09-13 |
| WO2007103787A3 (en) | 2007-11-15 |
| BRPI0708527A2 (en) | 2011-05-31 |
| CA2644708A1 (en) | 2007-09-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Oliviero et al. | MicroRNA in osteoarthritis: physiopathology, diagnosis and therapeutic challenge | |
| Iannitti et al. | Intra-articular injections for the treatment of osteoarthritis: focus on the clinical use of hyaluronic acid | |
| Oh et al. | Dkk‐1 expression in chondrocytes inhibits experimental osteoarthritic cartilage destruction in mice | |
| Bader et al. | Biomechanical influence of cartilage homeostasis in health and disease | |
| Altman et al. | The mechanism of action for hyaluronic acid treatment in the osteoarthritic knee: a systematic review | |
| Smith et al. | Beneficial effects of autologous bone marrow-derived mesenchymal stem cells in naturally occurring tendinopathy | |
| Pallotta et al. | Infrared (810-nm) low-level laser therapy on rat experimental knee inflammation | |
| Tsai et al. | Ciprofloxacin up‐regulates tendon cells to express matrix metalloproteinase‐2 with degradation of type I collagen | |
| Su et al. | NSAID therapy effects on healing of bone, tendon, and the enthesis | |
| Parkinson et al. | Change in proteoglycan metabolism is a characteristic of human patellar tendinopathy | |
| Korntner et al. | A high-glucose diet affects Achilles tendon healing in rats | |
| NZ582698A (en) | Treatment for traumatic synovitis and damaged articular cartilage with chondroitin sulfate, N-acetyl D-glucosamine and hyaluronan | |
| Haylock-Jacobs et al. | Chondroitin sulphate proteoglycans: extracellular matrix proteins that regulate immunity of the central nervous system | |
| Barr et al. | The effect of recombinant human fibroblast growth factor‐18 on articular cartilage following single impact load | |
| Jiang et al. | A brief review of current treatment options for osteoarthritis including disease-modifying osteoarthritis drugs (DMOADs) and novel therapeutics | |
| Ohtsuki et al. | High molecular weight hyaluronan protects cartilage from degradation by inhibiting aggrecanase expression | |
| MX2008011138A (en) | Treatment of tendinopathy by inhibition of molecules that contribute to cartilage formation. | |
| Fu et al. | mTORC1 coordinates NF-κB signaling pathway to promote chondrogenic differentiation of tendon cells in heterotopic ossification | |
| Hendesi et al. | Recombinant fibroblast growth factor‐18 (sprifermin) enhances microfracture‐induced cartilage healing | |
| Thomas et al. | Molecular determinants of neutrophil extracellular vesicles that drive cartilage regeneration in inflammatory arthritis | |
| Huang et al. | Therapeutic potential of SOX family transcription factors in osteoarthritis | |
| Izumi et al. | Inhibition of glucose use improves structural recovery of injured Achilles tendon in mice | |
| AU2011349256B2 (en) | Methods for treating neurological conditions and compositions and materials therefor | |
| Tajerian et al. | Spinal matrix metalloproteinase 8 regulates pain after peripheral trauma | |
| Chen et al. | Epigenetic and microRNA regulation during osteoarthritis development |